Abdominal Myomectomy



Fig. 11.1
Bonney’s myomectomy clamp (Adapted from Bonney [13], with permission)



A310782_1_En_11_Fig2_HTML.jpg


Fig. 11.2
Application of Bonney’s myomectomy clamp (Adapted from Bonney [13], with permission)




Preoperative Assessment


Comprehensive pre-operative assessment is essential in patients undergoing myomectomy. This should include a pelvic ultrasound scan to assess the site, size and number of fibroids. Where ultrasound findings are unclear an MRI should be considered. Radiological findings and local surgical expertise should guide whether an abdominal or laparoscopic myomectomy is offered, but in general if a single fibroid measures greater than 15 cm in diameter [11] or there are multiple fibroids (≥5) [10] an abdominal procedure should be offered. As many women undergoing myomectomy will have a history of menorrhagia the pre-operative period should also be used to optimise haemoglobin levels through iron therapy where needed, this will reduce the likelihood of requiring post-operative blood transfusion.

Consideration should also be given to the use of pre-operative agents to reduce the size of the fibroids. If used these should be given for 1–3 months, the longer the duration of use the more the shrinkage in volume. However, even after 3 months the shrinkage is rarely more than 30–50 %.

The two agents used are GnRH agonists (GnRHa) and more recently selective progesterone receptor modulators (SPRMs) such as Ulipristal Acetate. Of these the GnRHa are more effective in causing shrinkage but have more severe menopausal side effects such as hot flushes. The SPRMs cause fewer side effects and appear to induce a longer lasting shrinkage due to a presumed apoptotic effect that can be beneficial in women with multiple fibroids.

If there are numerous fibroids it is often not possible to remove all the small ones and the medium sized fibroids may have shrunk to a smaller size, which are less accessible at surgery. As such re-growth can recur very rapidly particularly after the use GnRHa where the shrinkage that it imposes is transient.

These agents should be considered particularly in women with large or multiple fibroids and have been associated with reduced rates of midline incisions, shorter hospital stays and higher postoperative haemoglobin levels [16], although their use did not affect operating time, operative blood loss or transfusion rates. Pre-operative counseling should also incorporate adequate informed consent highlighting particularly the risk of requiring a blood transfusion (approx. 8 % for large or multiple fibroids) [7], and the very small risk of requiring hysterectomy (<1 %) [7]. For those deemed to be at high risk of bleeding such as those with a very large, numerous fibroids or those awkwardly located in the cervix and deep in the lateral broad ligament, consideration should be given to the use of cell salvage [17] – something which is not possible with laparoscopic surgery.


Surgical Approach


The modern myomectomy technique has changed very little since Bonney first described the technique in 1946.


Abdominal Incision


As midline incisions are associated with increase perioperative [18] and postoperative morbidity where possible a low transverse abdominal or Pfannensteil incision should be used. Where uterine size is greater than 20 weeks consideration should be given to preoperative shrinkage of fibroids using GnRH agonists or SPRMs which may shrink the fibroids sufficiently to safely complete the procedure using a Pfannensteil approach [16].

More recently some have advocated undertaking abdominal myomectomy via a mini-laparotomy [19] (wound incision approximately 5 cm) or even an ultra-mini laparotomy [20] (wound incision <4 cm) which has been associated with reduced inpatient stays, shorter recovery time and improve cosmetic appearances compared to the traditional abdominal approach. This is appropriate where fibroids are not numerous or large.


Reduction of Uterine Blood Supply


Since Bonney [13] first described use of the Bonney’s clamp to temporarily occlude the uterine arteries and reduce uterine blood supply many other techniques have been used to reduce uterine blood supply and therefore minimise operative blood loss. The aim of these measures is to maximally restrict blood supply whilst limiting mechanical damage. Application of a pericervical tourniquet as an alternative to a clamp has been assessed [21], and has been shown to be associated with significant reductions in operative blood loss, although only when used in conjunction with occlusion of the ovarian arteries. More recently pharmacological developments have meant that vasopressors such as vasopressin [22] (diluted with normal saline) injected intramyometrially, resulting in local vasoconstriction, are now used to reduce intraoperative blood loss, avoiding the need for mechanical clamps or tourniquets which may cause inadvertent trauma. The use of intrauterine vasopressin injection has been associated with intraoperative morbidity such as hypotension, bradycardia, hypertension and asystole. Deaths have also been reported; as such this should be used with great care. Preferably a more dilute solution of vasopressin in normal saline, and using only a little at a time ensuring avoidance of blood vessels. If using vasopressin, it is also advisable that an experienced anaesthetist is on hand to deal with complications should they arise.


Enucleation of the Fibroid


The technique of enucleation of the fibroid from its capsule as first described by Bonney [13] is still used in modern practice [5]. Initially a serosal incision over the fibroid is made, the incision is then extended down through myometrium until the pseudocapsule is reached. Once the pseudocapsule is reached it is carefully incised to reach the surface of the fibroid. When reached the surface of the fibroid can be grasped or held with a myomectomy screw allowing gentle traction to be applied the fibroid whilst the plane of cleavage is opened up between the fibroid and the pseudocapsule by dividing fibres largely with blunt and sharp dissection to achieve enucleation or ‘shelling out’ of the fibroid from its capsule (Fig. 11.3).

A310782_1_En_11_Fig3_HTML.jpg


Fig. 11.3
Enucleation of the fibroid (Adapted from Bonney [13], with permission)

The technique has to be adapted to deal with fibroids that have degenerated; nevertheless a capsule should still be evident. Where a capsule is not easily identified, the presence of adenomyosis should be suspected.

To optimize future reproductive potential the route of the Fallopian tube should be identified and measures taken to avoid cutting or suturing the tubes.


Uterine Closure


Adequate closure of the uterus is essential not only to restore integrity of the uterine wall but also to ensure obliteration of the dead space thus avoiding haematoma formation and reducing postoperative febrile morbidity. This is usually achieved using two to three layers of continuous locking sutures within the myometrium (deep and more superficial) using an absorbable suture material. There are several techniques that have been described to effect closure including the herringbone, however of importance are close apposition of tissues and secure haemostasis even if interrupted sutures are used. If the endometrial cavity is inadvertently entered, this must be closed as an additional continuous layer.

Where there are submucous or partial submucous fibroids it is preferable to know if the cavity has been breeched, to this end it is the author’s practice to keep a Foley catheter (2 ml inflated balloon) within the uterine cavity via which blue dye can be instilled.


Adjuvant Measures


Since Bonney first described the technique, many adjuvant measures have been suggested with the aim of both reducing blood loss and reducing adhesion formation. Whilst, these measures may be useful in specific cases particularly in those at risk of bleeding, there is currently insufficient evidence to advocate use of these techniques routinely until further evidence of efficacy is available. Nevertheless, some of the measures advocated are described in the section below.


Pharmacological Measure to Reduce Blood Loss


Mechanical measures to reduce perioperative blood loss have already been discussed, however, other pharmacological agents in addition to vasoconstrictors have been employed to reduce operative blood loss.


Misoprostil


One randomised control trial [23] has assessed the benefit of a single dose of pre-operative misoprostil (400 mg) in patients undergoing abdominal myomectomy. Although a small study (only 13 patients per arm), compared to the control group who did not receive pre-operative misoprostil, the misoprostil group had significantly higher postoperative haemoglobin, significantly lower operative blood loss, significantly shorter operating time and significantly lower rates of post-operative blood transfusion. No other studies have assessed the potential benefits of pre-operative misoprostil.


Sodium-2-Mercaptoethanesulfonate (Mensa)


One randomised control trial [24] has assessed the efficacy of topical application of Mensa on the end of an operative needle in reducing operative blood loss. Mensa is a solution which chemically separates tissues and may be applied to the site of incision whilst dissection through the myometrium down to the surface of the fibroid is undertaken. Fifty-eight participants were either randomised to the Mensa group or a control group in which topical saline was applied. There were significantly shorter operating times and significantly higher post-operative haemoglobin levels in the Mensa group compared to controls. No other studies have assessed the value of Mensa in this setting.


Bupivicaine/Ephedrine


The benefits of infiltration of bupivacaine/ephedrine into the myometrium has only been assessed at laparoscopic myomectomy [25]. This study demonstrated a small but significant decrease in intraoperative blood loss and surgical duration in those receiving the intervention compared to the control arm. However, the benefits have not been assessed in the setting of open myomectomy.


Tranexamic Acid


One randomised control trial [26] has compared intraoperative Tranexamic acid infusion with placebo. A significantly lower operative blood loss and operating time were reported in the treatment arm, however there were no differences in rates of blood transfusion.


Gelatin-Thrombin Haemostatic Sealants


Gelatin-thrombin matrixes have been advocated as an adjunct to haemostasis for a number of surgical procedures. One group [27] have assessed its efficacy in reducing intraoperative blood loss at the time of abdominal myomectomy by randomising patients undergoing abdominal myomectomy to application of a gelatin-thrombin matrix at the site of uterine bleeding, in the control group no haemostatic sealant was used. Significantly reduced operating times, operative blood loss and rates of postoperative transfusion were seen in the treatment group, with higher mean postoperative haemoglobin levels in the treatment group.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

May 29, 2017 | Posted by in GYNECOLOGY | Comments Off on Abdominal Myomectomy

Full access? Get Clinical Tree

Get Clinical Tree app for offline access